口服伊特拉科纳可能会改变健康猫的胃肠道微生物群
American journal of veterinary research
|December 30, 2025
概括
口服伊特拉科纳可能会导致猫的肠道失调,改变它们的胃肠道微生物群. 需要进一步的研究来证实这些影响,并探索真菌评估方法.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 胃肠道微生物组在猫的健康中起着至关重要的作用.
- 像伊特拉可纳这样的抗真菌药物可能会影响肠道微生物群落.
研究的目的:
- 为了研究口服伊特拉科纳对健康猫的胃肠道微生物群的影响.
- 为了确定伊特拉可纳的使用是否会导致细菌或真菌失生症.
主要方法:
- 在一项涉及16只健康猫的纵向研究中,猫咪接受了口服伊特拉科纳.
- 收集直肠拭片进行细菌 (16S测序) 和真菌 (ITS测序) 分析.
- 评估微生物多样性 (α和β多样性) 和随着时间的推移差异的丰度.
主要成果:
- 在伊特拉科纳治疗前,细菌种群保持稳定.
- 在治疗期间和治疗后观察到β多样性的显著变化.
- 几种细菌种群在治疗后的相对丰度下降,尽管许多变化在长期内并不显著.
- 由于数据集规模较小,真菌分析受到限制.
结论:
- 初步证据表明,伊特拉科纳可能会在猫的胃肠道中诱导细菌失调.
- 观察到的微生物丰富度的变化往往是轻微和短暂的.
- 建议在未来对猫的真菌微生物组进行评估时采用替代方法.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
454
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
454
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
400
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
400
Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439
Drugs for Treatment of Diarrhea-Predominant IBS
593
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
593
Drugs for Treatment of Ulcerative Colitis in IBD
416
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
416
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
405
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
405


